After a review of evidence, the UK Health Security Agency (HSA) said today that it no longer classifies clade 1a and 1b mpox ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine ...

A public consultation on proposed changes to this document was held from December 2024 to March 2025. Based on the feedback received, this document may change. Learn about the consultation. Drugs ...

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, announced today the appointment of Retired United States Army ...

SIGA Technologies (SIGA) announced the appointment of Retired United States Army General John “Jack” Keane to its Board of Directors, effective ...

Bethesda, Maryland Saturday, March 15, 2025, 10:00 Hrs [IST] ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical ...

NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions. Colorized transmission electron micrograph of immature mpox virus particles (blue with red viral envelope) ...

83% of participants on tecovirimat achieved clinical resolution, compared to 84% on placebo, which was not significantly different. Pain reduction was similar in both groups, with tecovirimat ...

"The results from STOMP reinforce the value of randomized clinical trials during outbreaks of infectious diseases, like mpox, ...